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Abstract
Background: Malignant gliomas are the most common primary brain tumors in adults and challenging cancers for
diagnosis and treatment. They remain a disease for which non-invasive, diagnostic and/or prognostic novel
biomarkers are highly desirable. Altered microRNA (miRNA) profiles have been observed in tumor tissues and
biological fluids. To date only a small set of circulating/serum miRNA is found to be differentially expressed in brain
tumors compared to normal controls.
Here a restricted signature of circulating/serum miRNA including miR-15b*,-23a, −99a, −125b, −133a, −150*, −197,
−340, −497, −548b-5p and let-7c were investigated as potential non-invasive biomarkers in the diagnosis of glioma
patients.
Methods: Serum and tissues miRNAs expression in patients with brain cancers (n = 30) and healthy controls (n = 15)
were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Relative expression was calculated
using the comparative Ct method. Statistical significance (p ≤ 0,05) was determined using the Mann–Whitney rank
sum and Fisher’s exact test. Diagnostic accuracy of miRNAs in distinguishing glioblastoma multiforme (GBM) from
lower grade cancer was assessed by the Receiver Operating Characteristic (ROC) curve analysis.
To validate the role of the identified miRNAs in cancer a comprehensive literature search was conducted using
PubMed, Web of Science (Core Collection) and Scopus databases.
Results: We observed a decrease of miR-497 and miR-125b serum levels depending on tumor stages with reduced
level in GBM than lower grade tumors. The ROC curve analysis distinguishing GBM from lower grade cases yielded
an area under the curve (AUC) of 0.87 (95 % confidence interval (CI) = 0.712–1) and of 0.75 (95 % CI = 0.533–0.967)
for miR-497 and -125b, respectively. GBM patients are more likely to show a miR-497 and -125b down-regulation
than the lower grade group (p = 0.002 and p = 0.024, respectively). These results were subsequently compared with
evidence from 19 studies included in the final systematic review.
Conclusions: Although multiple biomarkers are currently leveraged in the clinic to detect specific cancer types, no
such standard blood biomolecules are used as yet in gliomas. Our data suggest that serum miR-497 and -125b
could be a novel diagnostic markers with good perspectives for future clinical applications in patients with glioma.
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Background
Malignant gliomas and mainly glioblastomas multiforme
(GBMs), represent the most lethal primary brain tumors
and are associated with high morbidity, presenting unique
challenges to therapy due to their location, aggressive bio-
logical behaviour and diffuse infiltrative growth [1, 2] ac-
cording to current World Health Organization (WHO)
guidelines, gliomas are subcategorized by histopathologic
evaluation into four tumor grades (I–IV), where GBM
(grade IV) is the most malignant and most common pri-
mary brain tumor [3]. Currently, histological examination
of the tumor tissue is the standard procedure for definitive
diagnosis of glioma, while computer tomography and nu-
clear magnetic resonance imaging (MRI) are the supple-
ment procedures for disease staging [4–6]. However, both
the histopathology and neuroimaging tests are insensitive
and expensive, and may cause haemorrhage and neuro-
logic damages [7]. Thus, there is a major interest in devel-
oping biomarkers that allow for less expensive monitoring
of the disease in shorter time intervals [8]. Furthermore,
patients at high risk for surgery-associated mortality or
small tumors in eloquent areas of the brain could benefit
from the discovery of biomarkers for the confirmation of
GBM in order to avoid biopsy [9]. Although early detec-
tion with circulating biomarkers is an established method
in the diagnosis and treatment of many cancer types, diag-
nostic tests for gliomas are currently limited [10]. There-
fore, to have a set of markers for early detection is still a
primary goal to improve diagnosis and treatment of hu-
man gliomas.
MicroRNAs (miRNAs) are small non-coding RNAs
that play an important role in the regulation of various
biological processes through their interaction with cellu-
lar messenger RNAs [11]. They are frequently deregu-
lated in cancer [12–14] and have shown great potential
as tissue-based markers for cancer classification and
prognosis including gliomas [15–17]. MiRNAs are also
present in extracellular human body fluids such as blood
serum and plasma [18, 19]. Since miRNAs circulate in
the bloodstream in a highly stable, extracellular form,
they have become particularly appealing as potential
non-invasive biomarkers for detection of cancer [20–22].
Regarding gliomas, plasma miR-21, one of the most
intensively studied miRNAs in cancer biology, has been
found significantly higher in GBM patients than control
samples and it decreased significantly after tumor resec-
tion and concomitant radio/chemotherapy [23–25]. Re-
cently, a global serum miRNA signature in a large
cohort of malignant glioma patients has been reported.
In particular, seven serum miRNAs (miR-15b*, miR-23a,
miR-133a, miR-150*, miR-197, miR-497 and miR-548b-
5p) whose concentrations were significantly decreased in
serum of malignant astrocytoma patients compared to
normal controls have been identified [26]. Moreover,
differentially expressed serum miRNAs were found in
GBM patients and normal controls. In particular, miR-
576-5p, miR-340 and miR-626 were significantly overex-
pressed, whereas miR-320, let-7 g-5p and miR-7-5p
showed significantly low expression in GBM patients
[27]. Besides, Wu J et al. reported a predictive value of
serum miR-29 in a high-graded glioma screening [28].
Lastly, miR-125b, a member of the let-7c cluster widely
considered as ideal biomarker for clinical diagnosis of
various human cancers [29–31], has also been described
as potential glioma biomarker [32].
Although all these promising circulating biomarkers
have been suggested to have a prognostic and diagnostic
value for glioma tumors, they should be further tested
and evaluated in order to be widely accepted.
Here, we assessed the suitability of eleven selected
serum miRNAs, previously shown to be associated with
brain tumors [26, 27, 32], as potential non-invasive diag-
nostic tools for glioma patients.
Methods
Study design, patients and control subjects
The present study involved two phases. In the first
phase, the predictive performance of a restricted signa-
ture of serum miRNAs (miR-15b*, −23a, let-7c, −99a,
−125b, −133a, −150*, −197, −340, −497 and miR-548b-
5p) for glioma was assessed.
Preoperative serum samples were collected from 30
newly diagnosed brain tumors (22 primary glioma pa-
tients of WHO grades II-IV, 8 meningiomas) at the Re-
gina Elena National Cancer Institute. Healthy controls
(n = 15) were recruited at the same Institute from indi-
viduals seeking a routine health checkup and with no
evidence of disease and with age-, gender- and ethnicity-
matched to the patients.
Formalin-fixed and paraffin-embedded (FFPE) human
non-neoplastic brain tissue from autopsies and glioma
tissue matched to serum of patient included in the study,
were obtained from the Regina Elena National Cancer
Institute. The clinic-pathological features of all the pa-
tients are summarized in Table 1.
All participants gave written informed consent and the
Research Ethics Committee of Regina Elena National
Cancer Institute approved this investigation. Patient data
and samples were treated according to ethical and legal
standards adopted by the Declaration of Helsinki 2013.
In the second phase of the study an on-line literature
search, for miR-497 and miR-125b, was conducted in
PubMed (from 01/01/1946 to 05/01/2016), Web of
Science (Core Collection) (from 01/01/1990 to 05/01/
2016) and Scopus (from 01/01/2004 to 05/01/2016) data-
bases to obtain all the studies related to the predictive
diagnostic performance of these miRNAs in different can-
cers. Our search strategy was based on a combination of
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keywords and Boolean operators organized as follows: (1)
MicroRNA* OR “Micro RNA” OR “RNA Micro” OR
miRNA* OR pri-miRNA* OR stRNA* OR pre-miRNA*;
(2) Small AND Temporal AND RNA*; (3)1 OR 2; (4)
125b; (5)3 AND 4; (6) miR-125b OR microRNA-125b OR
hsa-mir-125b OR miRNA-125b OR micro-RNA-125b OR
pri-miRNA-125b OR stRNA-125b OR pre-miRNA-125b;
(7)5 OR 6; (8) “MicroRNAs”[Mesh]) AND 125b; (9)7 OR
8; (10)neoplas* OR tumo* OR cancer*; (11) 9 AND 10.
In Scopus and Web of Science MeSH terms were not
included in the search. The same strategy has been repli-
cated for miR-497 without passage 10 and 11 because,
considering the smaller number of citations found for this
miRNA, it was not necessary to further restrict the search
including the two final passages of the search strategy.
Three review authors independently screened titles
and abstracts in order to identify articles for eligibility.
Later the review authors independently screened the
full-text articles for eligibility. Both the screening for ti-
tles and abstracts and the full-text screening were per-
formed using a standardized form with explicit inclusion
and exclusion criteria. Studies from the initial literature
search have been considered qualified and included in
our review if they satisfied the following criteria: (1) full
articles in English (reviews were excluded); (2) articles
concerning the evaluation of cell-free miRNA in human
biofluids from cancer patients; (3) recruitment of more
than 10 participants for the study (4) sample collection
before surgical resection or other therapeutic treatments;
(5) no declared concomitance with other diseases; (6)
analysis of miRNA levels for diagnostic purposes. The
review authors resolved any disagreement by discussion.
Sample processing and RNA extraction
Blood samples of glioma patients were collected before
surgery, radiotherapy or chemotherapy in BD Vacutainer
serum tubes using a 21-gauge needle. The samples were
kept at room temperature (RT) for 30–60 min and then
centrifuged at RT for 20 min at 1200 g. The serum
transferred into sterile cryovials was aliquoted and
stored at −80 °C until further analysis.
To isolate extracellular circulating miRNA in serum
we used a kit that permits to obtain all circulating cell-
free miRNAs both from exosomes and associated pro-
teins (Ago proteins, nucleoplasmin, HDL, etc.). RNA
was extracted from 200 μl of serum and purified using
miRCURY RNA Isolation Kit – Biofluids (Exiqon
#300112 Vedbaek- Denmark) in accordance with manu-
facturer’s instructions. There is considerable sample-to-
sample variability in both protein and lipid content of
plasma and serum samples, which could affect efficiency
of RNA extraction, and could introduce potential inhibi-
tors of PCR. In order to minimize the technical variation
between replicates in down-stream PCR analysis we
added, for all isolations, spike-in non-human synthetic
miRNAs (RNA spike-in mix: UniSp2, UniSp4 and
UniSp5; Exiqon #203203) into the respective lysis/
denaturant buffer before combining with serum. To avoid
DNA contamination, all samples were subjected to on-
column rDNase treatment in accordance with manufac-
turer’s instructions. After extraction RNA was eluted in
50 μl RNase-free water. Furthermore, determination of
RNA yield is usually not possible by spectrophotometric
reading thus we used RNA amounts based on starting vol-
ume in the PCR reaction as a measure, combined with
subsequent quantification of spike-ins. RNA from FFPE
samples were extracted using the PureLink FFPE Total
RNA Isolation Kit (Invitrogen. Carlsbad, CA, USA) in ac-
cordance with manufacturer’s instructions. Total tissue
RNA, eluted in RNase-free water, was quantified with the
NanoDrop ND-1000 spectrophotometer (ThermoFisher
Scientific, Wilmington, DE U.S.A.).
Table 1 General characteristics and clinicopathological features of brain tumor patients and control subjects
Variables Controls(n = 15) Gliomas(n = 22) Meningiomas (n = 8)
Age mean 51 54 61
range 29–65 24–82 27–76
Gender males 8 12 3
females 7 10 5
Neurological disordersa _ 6 _
Grade II/III _ 12 _
IV _ 10 _
IDH1 mutationb c _ 6 _
IDH2 mutationc _ 0 _
MGMT promoter methylatedd _ 12 _
a Hemisyndrome, psychiatric disorders, cognitive disorders
b mutation r132h
c 19 out of 22 patients analyzed for this mutations d MGMT promoter was considered methylated if the percentage of methylation was >5 %
14 out of 22 patients analyzed for methylation
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Reverse transcription and quantitative real-time -PCR
(qRT-PCR)
Quantification of the mature circulating and tissue miRNAs
were performed by a miRNA-specific LNA™-based system
using SYBR® Green (miRCURY LNA™ Universal RT micro-
RNA PCR; Exiqon # 203301, 203351 Vedbaek- Denmark).
First-strand cDNA was synthesized from 4 μl of each
serum RNA sample or 20 ng of tissue RNA, using the
Universal cDNA Synthesis kit II according to the Exiqon
manufacturer’s protocols with any modifications (Exiqon,
Vedbaek- Denmark). To control the potential presence of
inhibitors and the quality of the cDNA synthesis reaction
UniSp6 RNA Spike-in template was added to the Reverse
Transcription mixture.
The cDNA template was diluited 40x in nuclease-free
water and then amplified using microRNA-specific
LNA™-enhanced forward and reverse primers. QRT-PCR
was performed employing an ABI 7900 Real Time PCR
System and SDS 2.2.2 software (Applied Biosystems,
Foster City, CA). All reactions were performed in
triplicate and for the background level a No Template
Control was included in the study every time a new ex-
periment was set-up. ROX passive reference dye was
added in the diluited cDNA samples to obtain a robust
read over the entire array of wells (ROX high, Kapabio-
systems, Wilmington, Massacchusetts, USA). Expression
data for miRNAs were analyzed calculating cycle thresh-
old (Ct) values as well as standard deviations by means
of comparative ΔCt method. The quantity of serum and
tissue miRNAs was normalized as described below.
Established consensus house-keeping miRNAs for data
normalization are lacking for serum miRNAs. Exiqon man-
ufacturer’s protocols suggest miR-103-3p as a candidate en-
dogenous reference gene but it showed high variation in
our samples. Thus, in order to minimize variation in cir-
culating miRNA recovery, retro-transcription and amplifi-
cation efficiency, we normalized serum miRNA levels
measuring the expression of the synthetic spiked-inUniSP2
(UniSP2 LNA control primer set UniRT, Exiqon#203950).
The expression levels of mature tissue miRNAs were
normalized to the U6 snRNA (U6 snRNA LNA primer
set UniRTExiqon #203907).
As the major source of variation in plasma and serum
miRNA expression patterns is potential cellular derived
miRNA contamination including hemolysis [33] we
screened selected samples for hemolysis analyzing the ex-
pression levels of miR-451, abundant in red cells, and
miR-23a, unaffected by hemolysis, as suggested by Exiqon
manufacturer’s protocols (samples with Ct miR-23a – Ct
miR-451 ≥ 5 are considered hemolyzed).
Statistical analyses
Statistical significance (p ≤ 0,05) was determined using
the Mann–Whitney rank sum and Fisher’s exact test,
when appropriate. MiRNA expression values were plot-
ted into box-plots. Receiver operative characteristics
(ROC) curves were used to assess the diagnostic accur-
acy of miRNAs in distinguish high grade from lower
grade cancer. Youden’s index was performed to identify
the best cut-off value. Across various cut-off points,
Youden’s index maximized the difference between sensi-
tivity and specificity and between real-positive and false-
positive subjects. All analyses were carried out with SPSS
(version 21.0) statistical program (SPSS Inc., Chicago, IL,
USA).
Results and Discussion
The conventional method for glioma detection is neuro-
imaging, which is considered as gold standard but can
hardly avoid limitations such as invasive process, expen-
sive cost, and unwarrantable accuracy [5, 6, 21, 34].
Therefore, to have a set of markers for early detection is
still a primary goal to improve diagnosis and treatment
of human gliomas. To overcome these shortcomings,
biomarkers in blood have become a hot research field.
Since most current protein biomarkers cannot reach cer-
tain level of sensitivities or specificities, miRNAs, which
can be sampled non-invasively and cost-effectively, are
widely studied as ideal biomarkers for clinical applica-
tions [35].
Expression level of a selected subset of serum miRNAs in
a cohort of glioma patients
Circulating miRNAs, previously shown to be associated
with brain tumors, were evaluated as potential non-
invasive diagnostic biomarkers in the serum of a cohor-
tofpatients with brain tumors including gliomas of
different grade (n = 22), meningiomas (n = 8) and normal
control subjects (n = 15) with a matched distribution of
age and sex. An overview of the patient characteristics is
provided in Table 1.
In particular, we profiled by qRT-PCR the expression
level of eight serum miRNAs selected from the literature
(miR-15b*, −23a, −133a, −150*, −197, −340, −497 and
miR-548b-5p [26, 27] and three miRNAs from empirical
data from in-house studies (let-7c, −99a, −125b). As
shown in Fig. 1, we found that in GBM patients only
serum miR-497 was significantly down-regulated (−4,8
folds; p ≤ 0.01) compared to healthy donors. Interest-
ingly, when patient samples were clustered based on
histological grade, a statistically significant decrease of
the mean serum miR-497 expression (−3,75 fold; 73.3 %)
but also of miR-125b (−1,8 fold; 43.6 %) was evident in
high-grade relative to lower grade samples. Moreover,
benign brain tumors as meningiomas showed levels of
these miRNAs comparable to control samples (Fig. 1).
IDH mutation and MGMT methylation are grade-
dependent markers in glioma specimens [36, 37].
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Interestingly, regarding IDH1 mutation status, we ob-
served that patients who carry the IDH1 R132H muta-
tion, usually associated with a lower grade glioma [38],
are more likely to have levels of miR-125b and −497
higher while patients carrying IDH-wild type gene have
levels of miR-125b and −497 lower than the cut-off
values (data not shown). As far as methylation status, it
is of interest to note that, although lacking strong statis-
tical significance due to the low number of samples
available, the unmethylated condition, that is described
to be associated with a resistence to chemotherapy [38],
seems to be tendentially associated with levels of miR-
125b and −497 lower than the cut-off values (data not
shown).
These results suggest a possible diagnostic application of
miR-497 and -125b in determining the tumor grade in gli-
omas before biopsy or surgical resection, that are usually re-
quired for histopathological classification and grading [10].
However, our analysis did not recapitulate, except for
miR-497 and miR-125b, the results of previous studies
[26, 27] that identified all the miRNAs of the signature
as modulated in gliomas compared with normal control.
This contrastating data may be explained with the sev-
eral challenges in studying circulating miRNA. In fact,
while we are confident that in the case of miR-340 the
main key limiting factor for the absence of modulation
in glioma is the small sample size of the Dong et al.
study (miRNA profiles from only 3 circulating blood
samples of GBM patients and 3 matched healthy con-
trols) for the other selected miRNAs the conflicting re-
sults may resides on the many factors that can affect the
analysis and the evaluation of circulating miRNAs ex-
pression [25, 39].
A major obstacle to the translation of circulating miR-
NAs from laboratory studies into the clinic is the lack of
consistent and robust results with many apparently
contradictory reports in the literature [40]. A likely rea-
son for this lack of reproducibility is that there are very
few multi-center studies, and cohorts are often insuffi-
ciently powered. Another confounding factor is the fact
Fig. 1 Expression levels of selected miRNAs in a cohort of patients with brain tumors. Box-plot diagrams of relative miRNA expression levels in
pre-operative serum samples from glioblastoma (GBM; n = 10), lower grade glioma (G II/III; n = 12), meningioma (M; n = 8) patients and healthy
subjects (Ctrl; n = 15), assessed by qRT–PCR. Boxes define the 25th and 75th percentiles; the horizontal line into the boxes indicates the median,
and bars define the minimum and maximum values. The expression levels of mature miRNAs were normalized to volume and UniSp2 spike-in
RNA. Relative expression was calculated using the comparative ΔCt method. p-values (* = p≤ 0,05; ** = p≤ 0,01) were determined using the
Mann–Whitney rank sum test
Regazzo et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:124 Page 5 of 11
that there is a high degree of inter-individual variability
in the levels of circulating miRNAs, even when focusing
only on healthy populations [41]. Moreover, there is a
technical source of variation between studies, such as
the starting material used for the experiments (e.g., the
choice of use serum or plasma, the RNA extraction
method, the normalization, etc.), the technological
platforms [e.g., microarray, qRT-PCR vs. next generation
sequencing (NGS) etc.], and the differing statistical
methodologies used.
Diagnostic accuracy of serum miR-497 and miR-125b
To further explore the diagnostic potential and discrim-
inatory accuracy of serum miR-497 and miR-125b in gli-
oma patients, the ROC curves were established. The
ROC analyses revealed that serum miR-497 and miR-
125b levels were robust in discriminating patients with
GBM from lower grade gliomas, with an AUC value 0.87
(95 % CI = 0.712– 1) and of 0.75 (95 % CI = 0.533–0.967)
respectively (Fig. 2 a, b). The highest accuracy was at a
cut-off expression value 0.00083 (miR-497) and 0.00065
(miR-125b), where the negative predictive value, positive
predictive value, sensitivity, and specificity to identify a
patient with GBM were 0.909, 0.800, 0.889, 0.833 for
miR-497 and 0.889, 0.667, 0.889, 0.667 for miR-125b.
We became interested in evaluating if the combination
of miR-497 and miR-125b could have an increased
diagnostic accuracy. For this purpose, a miRNA panel
was created by a dummy variable assigning value 1 to
the patients who had a decrement of both the miR-497
and -125b and 0 for the other combinations (Fig. 2c).
The cut-off used to identify patients with modulated
miRNAs were obtained from the ROC curves shown in
Fig. 2a and b. Our analysis indicate that no substantial
improvement in the diagnostic performance was ob-
served between single or combined use of the two miR-
NAs (Fig. 2c). This is mainly due to the excellent
performance of miR-497 (AUC = 0.870) that flattens the
result of miR-125b (AUC = 0.750) which however remain
a good marker. Nevertheless, taking into account the
a b
c d
Fig. 2 ROC curves of serum miR-125b and miR-497 to discriminate glioblastomas from lower grade gliomas. a-b ROC curve plotted for diagnostic
potential and discriminatory accuracy of serum miR-497 and miR-125b to distinguish GBM from G II/III gliomas. The corresponding AUC, sensitivity
and specificity values are reported. c ROC curve for the combined miR-497/-125b panel by a dummy variable with value 1 for patients with decrement
of both miRNAs and 0 for the other combinations. d The histogram represents the distribution, between GBM and lower grade gliomas (G II/III), of the
patients with miRNA expression levels lower than the cut-off values (0,00083 for miR-497 and 0,00065 for miR-125b). p-values (* = p≤ 0,05; ** =≤ 0,01)
were determined using the Fisher’s exact test
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patients with an expression level of miRNAs lower than
the cut-off value, the number of subjects belonging to
the group of GBMs is significantly higher than the num-
ber of patients affected from glioma GII/III (Fig. 2d).
This difference can be observed for both miR-497 and
-125b and is more evident if we take into consideration
the patients with both miRNAs down-regulated.
As the comparison of the miRNA expression patterns
between serum and tissues may provide additional evi-
dence supporting the use of serum miRNAs as reliable
diagnostic biomarkers, we examined the expression of
miR-497 and -125b in paired tissue samples of glioma
patients and in normal brain from autopsy. Consistent
with the results in serum, we found decreased expres-
sion of the two identified miRNAs in tumor samples
relative to normal, post-mortem brain tissues (Fig. 3).
Thus, these data can indirectly support the advantage of
our miRNA detection technique in serum compared to
those used in previously published reports [26, 27].
However, while miR-497 and miR-125b levels in serum
distinguish high-grade from lower grade glioma, in
tumor samples they only distinguish tumor from normal
samples. This different results may reflect a yet un-
known biological phenomenon of physiological signifi-
cance ranging from the nature of the blood as a
systemic biofluid to the relative amount/stability that
miRNAs can have in different body districts [42]. More-
over the detailed knowledge of the molecular mecha-
nisms governing miRNAs release from normal and
tumour tissues is still lacking since the debate about the
relative contribution of organs and/or tissue to miRNAs
in blood plasma is still open [18, 40, 43]. Anyway, abun-
dant evidence shows that circulating nucleic acids in on-
cologic patients are dramatically altered with respect to
healthy individuals, suggesting that the tumour bulk
could be the major contributor in nucleic acid release in
bloodstream [44, 45]. In addition, we can hypothesize
that the tumor mass could indirectly affect circulating
miRNA profiles inducing or inhibiting non neoplastic
tissues to release biomolecules in blood.
Systematic review of the diagnostic value of miR-497 and
miR-125b in tumors
Finally, a systematic review was conducted in order to
have an overview on the role of the two identified miR-
NAs in cancer and to validate their possible use as non-
invasive biomarkers for diagnostic purposes. For this
reason we performed a literature research in multiple
databases with the aim of evaluating the results of all the
available articles concerning the expression of miR-497
and -125b in human cancers, focusing on the studies
conducted only in biofluid samples. After having per-
formed the screening of titles and abstracts of all the cita-
tions obtained by the initial literature search (Fig. 4), a
total of 42 full-text articles were retrieved and 19 of them
fulfilled the inclusion criteria described in the “Methods”
section and were eligible studies for the systematic review.
All the articles included in the final review are reported in
Table 2 where the main characteristics and the results of
each study are also summarized in terms of tumor or bio-
fluid type and comparison of the level of miRNA between
cases and controls [26, 32, 46–62].
MiR-497 is organized in a cluster with miR-195, lo-
cated on chromosome 17p13.1 [63]. It belongs to the
miR-15/107 family whose members share the same seed
sequence end are widely expressed in many human tis-
sues [64] and in particular in brain tissues miR-497 has
been reported expressed and functionally relevant in
mouse [65]. Its role in cancer has been investigated in
many tumor tissues and cell lines [63, 66–68]. In the
majority of these studies miR-497 is reported to have a
tumor suppressor activity and regulates numerous path-
ways involved in cellular proliferation, migration, invasion
Fig. 3 Expression levels of miR-497 and miR-125b in serum and
matched tissue samples of glioma patients. Scatter plots of the
normalized expression levels of miR-497 and -125b. The left ordinate
axis: miRNA levels in serum; the right ordinate axis: miRNA levels in
tissue samples. The horizontal line indicates the median. A Mann–
Whitney U test was conducted to compare the levels of miRNAs in
tumor samples (GBM n = 9; GII/III n = 6) and normal brain tissues (Ctrl
n = 4). Mature miRNAs were normalized to volume and UniSp2
spike-in RNA for serum and to U6 snRNA for tissue miRNAs. Relative
expression was calculated using the comparative ΔCT method.
p-values (** = p≤ 0,01) were determined using the Mann–Whitney
rank sum test
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and in angiogenesis [60, 66, 67] For example this miRNA
is dowregulated in bladder cancer where it represses the
inhibitor of apoptosis BIRC5 [63]. Moreover it inhibits
angiogenesis and metastasis formation in a murin model
of hepatocellular carcinoma through direct repression of
VEGFA and AEG-1 protein level [66]. So far very few
studies have been conducted about the role of miR-497 in
gliomas. Lan et al. reported it overexpressed in glioma tis-
sues and cell lines in response to hypoxia and observed a
relationship between miR-497 upregulation and resistance
to temozolomide [69]. On the other hand this miRNA,
thanks to its repressive action on VEGFA, seems to medi-
ate the inhibition of glioblastoma tissue vascularisation de-
termined by ginsenoide Rh2 in an in vivo murine model
[70]. According to our systematic review, miR-497 expres-
sion in biofluids appears to be so far less investigated than
miR-125b, the other miRNA evaluated in the present
study. All the studies shown in Table 2 are conducted on
blood samples and the majority of them report miR-497
to be downregulated in patients compared to healthy con-
trols [26, 59–61]. In the experiments performed by Yang
et al. in astrocytoma patients miR-497 appears to be
Table 2 Studies included in the systematic review
MicroRNA Cancer type Biofluid type Deregulation Author Reference
miR-125b Bladder cancer Urine ↓ tumors vs controls Zhang et al. 46
↓ high-grades vs low-grades
Uveal Melanoma Plasma ↑tumors vs controls Achberger et al. 47
Advanced Melanoma Seruma ↓tumors vs controls Alegre et al. 48
Ewing’s sarcoma Serum ↓ tumors vs controls Nie et al. 49
Breast cancer Serum ↑ late stages vs controls Wang et al. 50
↑ late stages vs early stages
Breast cancer Urine ↓ tumors vs controls Erbes et al. 51
Breast cancer Serum ↑ tumors vs controls Mar-Aguilar et al. 52
Breast cancer Serum ↑ tumors vs controls Matamala et al. 53
Non-small-cell lung cancer Serum ↑ tumorsvs controls Yuxia et al. 54
↑ late stages vs early stages
Non-small-cell lung cancer Plasma ↑ tumors vs controls Zhao et al. 55
↑ late stages vs early stages
Diffuse large B-cell lymphoma Serum ↑ tumors vs controls Yuan et al. 56
Laryngeal squamous cell carcinoma Plasma ↓ tumors vs controls Ayaz et al. 57
Glioma Serum ↓ tumors vs controls Wei et al. 32
↓ high-grades vs low-grades
Colorectal neoplasia Serum ↑ tumors vs controls Yamada et al. 58
miR-497 Bladder cancer Plasma ↓ tumors vs controls Du et al. 59
Astrocytoma Serum ↓ tumors vs controls Yang et al. 26
Nasopharyngeal carcinoma Plasma ↓ tumors vs controls Wang et al. 60
Prostate cancer Serum ↓ tumors vs controls Kong et al. 61
Cervical cancer Serum ↑ tumors vs controls Zhang et al. 62
aExosomal fraction only
All citations identified by
literature search of electronic
databases (PubMed, Web of













Studies included in our Systematic 
Review:
n=19
Abstracts assessed for eligibility:
n=42
Fig. 4 Flow diagram of the study selection process
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underexpressed in GBM serum samples in accordance
with our results [26].
Regarding miR-125b, naturally express at high levels in
brain tissue and in the ovarian tissue [71], it is highly
conserved among mammals, vertebrates and nematodes
[72]. In humans, as in most of the genomes, there are
two paralogs (hsa-miR-125b-1 on chromosome 11 and
hsa-miR-125b-2 on chromosome 21), coding for the
same mature sequence. MiR-125b-2 is organized in a
cluster with miR-99a and let-7c [73].
MiR-125b has been observed to be deregulated in solid
tumors, for example it is overexpressed in prostate [74],
colorectal cancers [75] and non-small-cell lung cancers
[76], whereas it is downregulated in breast [77], oral can-
cers [78], melanoma [79], hepatocellular [80], thyroid
anaplastic carcinomas [81], and bladder cancer [82]. The
role of miR-125b in gliomas appears to be controversial.
While it is described as an oncogene [83, 84] it is re-
ported also to be downregulated in glioma stem cells
and to have an anti-angiogenic role [85]. This controver-
sial role is described also in the studies about miR-125b
expression in biofluids [32, 46–58]. In accordance with
our data, experiments conducted in glioma from Wei
et al. report miR-125b to be downregulated in serum
tumor samples [32]. Surprisingly, in our cohort of sub-
jects, the expression of miR-125b in not correlated with
that of the other members of the cluster, miR-99a and
let-7c. This could be explained by the fact that the same
mature form of miR-125b is encoded not only in the let-
7c cluster but also in another locus on chromosome 11.
Interestingly, in the context of bliofluids, the expression
of miR-125b seems to be dependent not only from the
type of tumor but also from the kind of biofluid exam-
ined: as an example in three out of four studies concern-
ing breast cancer, conducted on blood derived biofluids,
miR-125b is reported to be upregulated in serum tumor
samples [50, 52, 53], while it is described as downregu-
lated in the only study conducted on urine [51]. This de-
pendence of miRNA expression on the biofluid type has
already been described for other miRNAs [25]. More-
over, miR-125b seems to have a possible dual role de-
pending on the type or cellular context: it can act as
both an oncomiR or a tumor suppressor miR by target-
ing tumor suppressor genes or oncogenes respectively.
For example, on the one hand miR-125b targets multiple
genes involved in the p53 pathway and induces a block-
age of apoptosis in human neuroblastoma cells [29, 71,
86], on the other hand it can negatively affects the
expression of proteins involved in the regulation of
cellular proliferation as E2F3, ERBB2/3 [87] or the anti-
apoptotic protein Bcl2 [71], suggesting an oncosuppres-
sive role. Thus, the results of our systematic review join
a current trend to include circulating miR-497 and miR-
125b as good non-invasive diagnostic biomarkers for
several tumors [32, 47, 60]as they appear to be deregulated
in association with a variety of cancer types. This is valid
also in the case of miR-125b whose direction of deregula-
tion could be different in different kinds of tumor, due to
the dual role of this miRNA as oncomiR or tumor sup-
pressor depending on cellular type or context [71, 76].
Conclusions
Although multiple biomarkers are currently leveraged in
the clinic to detect specific cancer types, no such stand-
ard blood biomolecules have been identified in glioma
patients [9, 10]. Thus, it is clear that identification of
new molecular glioma biomarkers with the aim of devel-
oping minimally invasive tests for the detection and
monitoring of glioma patients are demanded.
In this study we underlined the role of serum miR-497
and -125b as diagnostic markers and as mirrors of tissue
miRNA level in gliomas thus suggesting the clinical poten-
tial of these miRNAs to discriminate with high sensitivity
and specificity the GBM from lower grade gliomas. Never-
theless, challenges remain before miR-497 and -125b are
leveraged as bona fide biomarkers in glioma cancers and
further investigation from larger independent studies is
needed to unveil their clinical relevance.
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